STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma
Tiffany S. Nelson, Cathrine Pacini, Amy Nguyen, Travis M. Zeigler, Alexa Ziff, Kimberly Paulsen, Alayna Simpson, Sumita Bhaduri-McIntosh, Zhe Ma · 2026
Read STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma by Tiffany S. Nelson, Cathrine Pacini, Amy Nguyen, Travis M. Zeigler, Alexa Ziff, Kimberly Paulsen, Alayna Simpson, Sumita Bhaduri-McIntosh, Zhe Ma (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13183639.txt.
Description
Tiffany Nelson and co-authors studied in 2026 a defense protein that may hold back a virus-linked blood cancer. The virus behind Kaposi's sarcoma can also cause primary effusion lymphoma, a cancer tied to weak immunity. Care for it is limited and rarely cures. The protein, called STING, helps the body sense viral DNA and fight tumors.
The team profiled cancer cell lines from patients and found wide gaps in STING levels. In a line with strong STING, a drug that switches it on sharply cut the virus waking from rest and slowed cell growth. A line with weak STING barely responded. Blocking STING sped growth, while adding it back slowed growth in both lines. The authors argue the pathway acts as a natural barrier worth targeting.
Catalog record
| CREATOR | Tiffany S. Nelson, Cathrine Pacini, Amy Nguyen, Travis M. Zeigler, Alexa Ziff, Kimberly Paulsen, Alayna Simpson, Sumita Bhaduri-McIntosh, Zhe Ma |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |